These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

379 related articles for article (PubMed ID: 29039233)

  • 1. The relationships of classic psychedelic use with criminal behavior in the United States adult population.
    Hendricks PS; Crawford MS; Cropsey KL; Copes H; Sweat NW; Walsh Z; Pavela G
    J Psychopharmacol; 2018 Jan; 32(1):37-48. PubMed ID: 29039233
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Psilocybin use is associated with lowered odds of crime arrests in US adults: A replication and extension.
    Jones GM; Nock MK
    J Psychopharmacol; 2022 Jan; 36(1):66-73. PubMed ID: 35090364
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prevalence and epidemiological associates of novel psychedelic use in the United States adult population.
    Sexton JD; Crawford MS; Sweat NW; Varley A; Green EE; Hendricks PS
    J Psychopharmacol; 2019 Sep; 33(9):1058-1067. PubMed ID: 30816808
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Classic psychedelic use is associated with reduced psychological distress and suicidality in the United States adult population.
    Hendricks PS; Thorne CB; Clark CB; Coombs DW; Johnson MW
    J Psychopharmacol; 2015 Mar; 29(3):280-8. PubMed ID: 25586402
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Hallucinogen use predicts reduced recidivism among substance-involved offenders under community corrections supervision.
    Hendricks PS; Clark CB; Johnson MW; Fontaine KR; Cropsey KL
    J Psychopharmacol; 2014 Jan; 28(1):62-6. PubMed ID: 24399338
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cessation and reduction in alcohol consumption and misuse after psychedelic use.
    Garcia-Romeu A; Davis AK; Erowid F; Erowid E; Griffiths RR; Johnson MW
    J Psychopharmacol; 2019 Sep; 33(9):1088-1101. PubMed ID: 31084460
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Associations between lifetime classic psychedelic use and cardiometabolic diseases.
    Simonsson O; Osika W; Carhart-Harris R; Hendricks PS
    Sci Rep; 2021 Jul; 11(1):14427. PubMed ID: 34257396
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The Psychedelic Renaissance and Its Forensic Implications.
    Holoyda B
    J Am Acad Psychiatry Law; 2020 Mar; 48(1):87-97. PubMed ID: 31948993
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Associations between lifetime classic psychedelic use and markers of physical health.
    Simonsson O; Sexton JD; Hendricks PS
    J Psychopharmacol; 2021 Apr; 35(4):447-452. PubMed ID: 33719688
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Psychedelic use and intimate partner violence: The role of emotion regulation.
    Thiessen MS; Walsh Z; Bird BM; Lafrance A
    J Psychopharmacol; 2018 Jul; 32(7):749-755. PubMed ID: 29807492
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The use of classic psychedelics among adults: a Danish online survey study.
    Søgaard Juul T; Ebbesen Jensen M; Fink-Jensen A
    Nord J Psychiatry; 2023 May; 77(4):367-378. PubMed ID: 36173202
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Psychedelics and mental health: a population study.
    Krebs TS; Johansen PØ
    PLoS One; 2013; 8(8):e63972. PubMed ID: 23976938
    [TBL] [Abstract][Full Text] [Related]  

  • 13. MDMA/ecstasy use and psilocybin use are associated with lowered odds of psychological distress and suicidal thoughts in a sample of US adults.
    Jones GM; Nock MK
    J Psychopharmacol; 2022 Jan; 36(1):46-56. PubMed ID: 34983249
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Lifetime use of MDMA/ecstasy and psilocybin is associated with reduced odds of major depressive episodes.
    Jones GM; Nock MK
    J Psychopharmacol; 2022 Jan; 36(1):57-65. PubMed ID: 34983261
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The association of psychedelic use and opioid use disorders among illicit users in the United States.
    Pisano VD; Putnam NP; Kramer HM; Franciotti KJ; Halpern JH; Holden SC
    J Psychopharmacol; 2017 May; 31(5):606-613. PubMed ID: 28196428
    [TBL] [Abstract][Full Text] [Related]  

  • 16. d-Lysergic acid diethylamide, psilocybin, and other classic hallucinogens: Mechanism of action and potential therapeutic applications in mood disorders.
    De Gregorio D; Enns JP; Nuñez NA; Posa L; Gobbi G
    Prog Brain Res; 2018; 242():69-96. PubMed ID: 30471683
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Knowledge, Perceptions, and Use of Psychedelics among Individuals with Fibromyalgia.
    Glynos NG; Pierce J; Davis AK; McAfee J; Boehnke KF
    J Psychoactive Drugs; 2023; 55(1):73-84. PubMed ID: 35001856
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Associations between classic psychedelics and opioid use disorder in a nationally-representative U.S. adult sample.
    Jones G; Ricard JA; Lipson J; Nock MK
    Sci Rep; 2022 Apr; 12(1):4099. PubMed ID: 35393455
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Classic psychedelic drugs and their potential therapeutic effect].
    Bayat M
    Ugeskr Laeger; 2017 Sep; 179(37):. PubMed ID: 28918777
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Population Survey Data Informing the Therapeutic Potential of Classic and Novel Phenethylamine, Tryptamine, and Lysergamide Psychedelics.
    Sexton JD; Nichols CD; Hendricks PS
    Front Psychiatry; 2019; 10():896. PubMed ID: 32116806
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.